SGS introduces new bio-layer interferometry analysis for biopharmaceutical development
This new service offers a number of advantages compared with current analytical techniques.
SGS is introducing bio-layer interferometry (BLI) for the analysis of molecular interactions in real time, at its laboratory in Mississauga, Canada. This new service leverages the capabilities of the Octet Red96 System to detect specific interactions between a biosensor and a target analyte, and offers a number of advantages over current analytical techniques.
BLI utilizes the principle of optical interferometry to generate real time binding curves. An optic fiber is coated with a specific capture molecule, such as a monoclonal antibody, and binding of a target analyte to the biosensor is monitored using an algorithm which then converts interference patterns into a binding curve. This method can be used to study interactions between most types of molecules, such as protein-protein, protein-small molecule, antibody-peptide, DNA-protein or DNA-DNA. The data generated by the newly installed instrument is 21 CFR part 11 compliant to ensure integrity of information for regulatory submissions. “BLI is a strong addition to the existing services that SGS offers for protein quantitation, molecular binding affinity and kinetic analysis,” commented Mike Lindsay, Vice President Life Sciences, SGS Canada. “This new technique enhances our ability to offer more robust, high-throughput, cost efficient and complete solutions to assist with candidate selection and assist in the drug-to-market process.”
In comparison with other techniques, BLI is easier to use, more cost effective and more tolerant of samples in complex mixtures, such as media and lysates. For molecular binding affinity/kinetics analysis, BLI provides rate and affinity constants in minutes, allowing for a high throughput method with small volumes. Additionally, protein quantitation can be performed over a large dynamic range (ng/mL to mg/mL), and samples do not need to be purified or diluted, reducing handling and assay time, and enhancing the accuracy of results. Furthermore, the BLI method conserves valuable samples as it is label-free and non-destructive.
The investment in BLI at its Mississauga facility comes after the December 2015 announcement of the acquisition of Quality Compliance Laboratories Inc., which expanded SGS’s comprehensive service provision in the analytical testing of pharmaceutical and biopharmaceutical products, raw materials and packaging, and medical devices capacity from its three laboratories in Canada.
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance